A recent post hoc analysis assesses whether PSA changes can predict survival outcomes in patients with metastatic or very high risk nonmetastatic prostate cancer.

A new blood test could help doctors identify whether a treatment for advanced prostate cancer is failing weeks earlier than ...

New blood test could show if prostate cancer treatment is failing - The discovery could lead to personalised treatments for ...

Genomic and transcriptomic correlates of deep PSA response in patients with mHSPC. Despite major advances in combination treatment strategies for metastatic hormone-sensitive prostate cancer (mHSPC), ...

Prostate cancer is the most common cancer in Australia, with about 26,000 men diagnosed per year. The majority (more than 85%) are aged over 60. Prostate cancer kills around 3,900 Australians a year.

Editor's note: Dr. Jamin Brahmbhatt is a urologist and robotic surgeon with Orlando Health and an assistant professor at the University of Central Florida’s College of Medicine.When I learned that ...

Prostate-specific antigen (PSA) is a protein made by the prostate gland. A high PSA level could be a sign of an enlarged prostate, inflammation called prostatitis, or prostate cancer. The PSA test ...

Prostate cancer kills more than 10,000 men in England each year. For decades, urologists across the country have been ...